Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology
- 101 Downloads
Anaplastic thyroid cancer (ATC) is among the most aggressive and unresectable tumors, presenting a bad prognosis. A better comprehension of the functional and molecular mechanisms behind the aggressiveness of this cancer, as well as new biomarkers for aggressiveness, prognosis, and response to therapy are required. However, owing to their irresectability, ATC tissue is not always accessible. Here we describe the establishment and characterization of a new patient-derived cell line, obtained from an unresectable ATC through fine-needle aspiration cytology (FNAC).
The morphology, expression of epithelial and thyroid markers, cytogenetic, mutational and gene expression profiles, doubling time, and drug-resistance profile of the new cell line, designated C3948, were investigated using several methodologies: immunostaining, karyotype analysis, comparative genomic hybridization (CGH), fluorescent in situ hybridization (FISH), next-generation sequencing (NGS), Sanger sequencing, gene expression microarrays, cell counting, and IC50 determination.
Results indicate that C3948 cell line has a histological phenotype representative of original ATC cells and a completely aberrant karyotype with many chromosomal losses and gains; harbors mutated TP53, STK11, and DIS3L2 genes; presents a gene expression profile similar to C643 ATC commercial cell line, but with some unique alterations; has a doubling time similar to C643; and the IC50 profile for paclitaxel, doxorubicin, and cisplatin is similar to C643, although higher for cisplatin.
These observations are consistent with a typical ATC cell profile, supporting C3948 cell line as a novel preclinical model, and FNAC as a useful approach to better study anaplastic thyroid cancer, including testing of new anticancer therapies.
KeywordsAnaplastic thyroid cancer Tumor cell line Fine-needle aspiration cytology Genetic profile Cytogenetic techniques Molecular biology
The authors are thankful for the collaboration of the Endocrinology (Dr. Rita Santos) and Pathology Departments from Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG). This work was funded by Associação de Endocrinologia Oncológica (AEO), IPOLFG and iNOVA4Health Research Unit (LISBOA-01-0145-FEDER-007344), which is cofunded by Fundação para a Ciência e Tecnologia/Ministério da Ciência e do Ensino Superior, through national funds, and by FEDER under the PT2020 Partnership Agreement. M.P. was supported by Núcleo Regional Sul da Liga Portuguesa Contra o Cancro.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 1.M. Ragazzi, A. Ciarrocchi, V. Sancisi, G. Gandolfi, A. Bisagni, S. Piana, Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int. J. Endocrinol. 2014, 790834 (2014). https://doi.org/10.1155/2014/790834 CrossRefPubMedPubMedCentralGoogle Scholar
- 4.I. Landa, T. Ibrahimpasic, L. Boucai, R. Sinha, J.A. Knauf, R.H. Shah, S. Dogan, J.C. Ricarte-Filho, G.P. Krishnamoorthy, B. Xu, N. Schultz, M.F. Berger, C. Sander, B.S. Taylor, R. Ghossein, I. Ganly, J.A. Fagin, Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Invest. 126, 1052–1066 (2016). https://doi.org/10.1172/JCI85271 CrossRefPubMedPubMedCentralGoogle Scholar
- 5.J.W. Kunstman, C.C. Juhlin, G. Goh, T.C. Brown, A. Stenman, J.M. Healy, J.C. Rubinstein, M. Choi, N. Kiss, C. Nelson-Williams, S. Mane, D.L. Rimm, M.L. Prasad, A. Hoog, J. Zedenius, C. Larsson, R. Korah, R.P. Lifton, T. Carling, Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum. Mol. Genet. 24, 2318–2329 (2015). https://doi.org/10.1093/hmg/ddu749 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.J.M. Pita, I.F. Figueiredo, M.M. Moura, V. Leite, B.M. Cavaco, Cell cycle deregulation and TP53 and RAS mutations are major events in poorly differentiated and undifferentiated thyroid carcinomas. J. Clin. Endocrinol. Metab. 99, E497–E507 (2014). https://doi.org/10.1210/jc.2013-1512 CrossRefPubMedGoogle Scholar
- 7.R.C. Smallridge, K.B. Ain, S.L. Asa, K.C. Bible, J.D. Brierley, K.D. Burman, E. Kebebew, N.Y. Lee, Y.E. Nikiforov, M.S. Rosenthal, M.H. Shah, A.R. Shaha, R.M. Tuttle, American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce, American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22, 1104–1139 (2012). https://doi.org/10.1089/thy.2012.0302
- 9.H. Asakawa, T. Kobayashi, Y. Komoike, T. Yanagawa, M. Takahashi, E. Wakasugi, H. Maruyama, Y. Tamaki, Y. Matsuzawa, M. Monden, Establishment of anaplastic thyroid carcinoma cell lines useful for analysis of chemosensitivity and carcinogenesis. J. Clin. Endocrinol. Metab. 81, 3547–3552 (1996). https://doi.org/10.1210/jcem.81.10.8855799 CrossRefPubMedGoogle Scholar
- 10.M. Garg, R. Okamoto, Y. Nagata, D. Kanojia, S. Venkatesan, M.T.A., G.D. Braunstein, J.W. Said, N.B. Doan, Q. Ho, T. Akagi, S. Gery, L.Z. Liu, K.T. Tan, W.J. Chng, H. Yang, S. Ogawa, H.P. Koeffler, Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft. J. Clin. Endocrinol. Metab. 100, 725–735 (2015). https://doi.org/10.1210/jc.2014-2359 CrossRefPubMedGoogle Scholar
- 11.N. Onoda, M. Nakamura, N. Aomatsu, S. Noda, S. Kashiwagi, K. Hirakawa, Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors. World J. Surg. 38, 688–695 (2014). https://doi.org/10.1007/s00268-013-2409-7 CrossRefPubMedGoogle Scholar
- 12.F. Stenner, H. Liewen, M. Zweifel, A. Weber, J. Tchinda, B. Bode, P. Samaras, S. Bauer, A. Knuth, C. Renner, Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Sci. 99, 1847–1852 (2008). https://doi.org/10.1111/j.1349-7006.2008.00882.x CrossRefPubMedGoogle Scholar
- 13.A. Antonelli, S.M. Ferrari, P. Fallahi, P. Berti, G. Materazzi, I. Marchetti, C. Ugolini, F. Basolo, P. Miccoli, E. Ferrannini, Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur. J. Endocrinol. 159, 283–291 (2008). https://doi.org/10.1530/EJE-08-0190 CrossRefPubMedGoogle Scholar
- 14.J.D. Brierley, M.K. Gospodarowicz, C. Wittekind, TNM Classification of Malignant Tumours, 8th edn. (Wiley, Hoboken, NJ, 2017)Google Scholar
- 16.J. McGowan-Jordan, A. Simons, M. Schmid, ISCN 2016: An International System for Human Cytogenomic Nomenclature, vol. 149, 1st edn. Reprint of Cytogenetic and Genome Research (Karger, Basel, 2016)Google Scholar
- 22.L.A. Marlow, J. D’Innocenzi, Y. Zhang, S.D. Rohl, S.J. Cooper, T. Sebo, C. Grant, B. McIver, J.L. Kasperbauer, J.T. Wadsworth, J.D. Casler, P.W. Kennedy, W.E. Highsmith, O. Clark, D. Milosevic, B. Netzel, K. Cradic, S. Arora, C. Beaudry, S.K. Grebe, M.L. Silverberg, D.O. Azorsa, R.C. Smallridge, J.A. Copland, Detailed molecular fingerprinting of four new anaplastic thyroid carcinoma cell lines and their use for verification of RhoB as a molecular therapeutic target. J. Clin. Endocrinol. Metab. 95, 5338–5347 (2010). https://doi.org/10.1210/jc.2010-1421 CrossRefPubMedPubMedCentralGoogle Scholar
- 26.N. Pozdeyev, L.M. Gay, E.S. Sokol, R. Hartmaier, K.E. Deaver, S. Davis, J.D. French, P.V. Borre, D.V. LaBarbera, A.C. Tan, R.E. Schweppe, L. Fishbein, J.S. Ross, B.R. Haugen, D.W. Bowles, Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin. Cancer Res. 24, 3059–3068 (2018). https://doi.org/10.1158/1078-0432.CCR-18-0373 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.I. Landa, N. Pozdeyev, C. Korch, L.A. Marlow, R.C. Smallridge, J.A. Copland, Y.C. Henderson, S.Y. Lai, G.L. Clayman, N. Onoda, A.C. Tan, M.E.R. Garcia-Rendueles, J.A. Knauf, B.R. Haugen, J.A. Fagin, R.E. Schweppe, Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies. Clin. Cancer Res. (2019). https://doi.org/10.1158/1078-0432.CCR-18-2953 CrossRefGoogle Scholar
- 29.H. Ji, M.R. Ramsey, D.N. Hayes, C. Fan, K. McNamara, P. Kozlowski, C. Torrice, M.C. Wu, T. Shimamura, S.A. Perera, M.C. Liang, D. Cai, G.N. Naumov, L. Bao, C.M. Contreras, D. Li, L. Chen, J. Krishnamurthy, J. Koivunen, L.R. Chirieac, R.F. Padera, R.T. Bronson, N.I. Lindeman, D.C. Christiani, X. Lin, G.I. Shapiro, P.A. Janne, B.E. Johnson, M. Meyerson, D.J. Kwiatkowski, D.H. Castrillon, N. Bardeesy, N.E. Sharpless, K.K. Wong, LKB1 modulates lung cancer differentiation and metastasis. Nature 448, 807–810 (2007). https://doi.org/10.1038/nature06030 CrossRefPubMedGoogle Scholar
- 31.N. Hearle, V. Schumacher, F.H. Menko, S. Olschwang, L.A. Boardman, J.J. Gille, J.J. Keller, A.M. Westerman, R.J. Scott, W. Lim, J.D. Trimbath, F.M. Giardiello, S.B. Gruber, G.J. Offerhaus, F.W. de Rooij, J.H. Wilson, A. Hansmann, G. Moslein, B. Royer-Pokora, T. Vogel, R.K. Phillips, A.D. Spigelman, R.S. Houlston, Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin. Cancer Res. 12, 3209–3215 (2006). https://doi.org/10.1158/1078-0432.CCR-06-0083 CrossRefPubMedGoogle Scholar
- 33.Y. Naito, H. Takahashi, K. Shitara, W. Okamoto, H. Bando, T. Kuwata, Y. Kuboki, S. Matsumoto, I. Miki, T. Yamanaka, A. Watanabe, M. Kojima, Feasibility study of cancer genome alterations identified by next generation sequencing: ABC study. Jpn. J. Clin. Oncol. 48, 559–564 (2018). https://doi.org/10.1093/jjco/hyy052 CrossRefPubMedPubMedCentralGoogle Scholar
- 34.G. Zheng, H. Tsai, L.H. Tseng, P. Illei, C.D. Gocke, J.R. Eshleman, G. Netto, M.T. Lin, Test feasibility of next-generation sequencing assays in clinical mutation detection of small biopsy and fine needle aspiration specimens. Am. J. Clin. Pathol. 145, 696–702 (2016). https://doi.org/10.1093/ajcp/aqw043 CrossRefPubMedPubMedCentralGoogle Scholar